Stockscreener 앱 받기
3.93
3.69%
0.14
시간 외 거래:
3.93
Verastem Inc 주식(VSTM)의 최신 뉴스
B. Riley Forecasts Verastem's FY2024 Earnings (NASDAQ:VSTM) - MarketBeat
KRAS Inhibitors Market Report 2034: Epidemiology Data, - openPR
Data-Based Insights About Verastem Inc (VSTM) - Stocks Register
OrbiMed Advisors LLC's Strategic Acquisition of Verastem Inc Sha - GuruFocus.com
Alyeska Investment Group L.P.'s Strategic Acquisition of Veraste - GuruFocus.com
Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Verastem, Inc. (NASDAQ:VSTM) Receives $14.57 Average PT from Analysts - MarketBeat
Verastem's SWOT analysis: oncology firm's stock faces pivotal FDA decision - Investing.com India
Verastem's SWOT analysis: oncology firm's stock faces pivotal FDA decision By Investing.com - Investing.com Canada
Stonepine Capital Management, LLC Increases Stake in Verastem Inc - GuruFocus.com
Such Is The Power Of Verastem Inc (NASDAQ: VSTM) - Stocks Register
Verastem (NASDAQ:VSTM) Stock Rating Lowered by StockNews.com - Defense World
Verastem CEO Paterson sells $3,118 in common stock - Investing.com
Verastem CEO Paterson sells $3,118 in common stock By Investing.com - Investing.com UK
Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates - BioSpace
Verastem: Q3 Earnings Snapshot - The Washington Post
Verastem, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Chugai PharmaceuticalVerastem Oncology's Announcement Regarding Avutometinib - Marketscreener.com
Avutometinib With Defactinib for Recurrent KRAS Mutant LGSOC Completes Rolling New Drug Application - Pharmacy Times
Verastem Oncology submits NDA for ovarian cancer treatment - Yahoo Finance
Verastem (FRA:2VSA) Owner Earnings per Share (TTM) : -3.30 (As of Jun. 2024) - GuruFocus.com
Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer - StockTitan
Verastem Oncology to Participate in Upcoming Investor Conferences - BioSpace
SG Americas Securities LLC Purchases New Position in Verastem, Inc. (NASDAQ:VSTM) - Defense World
Verastem's SWOT analysis: ovarian cancer drug maker's stock faces pivotal year - Investing.com India
Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Verastem preps an NDA as the stock struggles - BioWorld Online
Verastem's (VSTM) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Verastem Holders Endure Difficult Day, Analysts Holding Firm (VSTM) - AskTraders
Truist keeps $15 target on Verastem amid sell-off By Investing.com - Investing.com UK
Verastem Advances Cancer Treatment with Promising Trial Results - TipRanks
Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting - StockTitan
This trade activity should not be overlooked: Verastem Inc (VSTM) - SETE News
Verastem Inc (VSTM) stock: A year of ups and downs - US Post News
Verastem CFO sells shares worth $17 to cover tax obligations By Investing.com - Investing.com Canada
Verastem CFO sells shares worth $17 to cover tax obligations - Investing.com India
Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting - StockTitan
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Verastem whipsaws after updates for cancer drug combo - MSN
Taking the lead: Verastem Inc (VSTM) - SETE News
Guggenheim’s latest rating for VSTM stock - Knox Daily
Verastem Inc’s results are impressive - US Post News
Nantahala Capital Management LLC Purchases Shares of 400,000 Verastem, Inc. (NASDAQ:VSTM) - Defense World
Verastem Inc (VSTM) Stock: A Year of Decreases and Increases - The InvestChronicle
Guggenheim Initiates Coverage of Verastem (VSTM) with Buy Recommendation - Nasdaq
0.93%
3.55%
자본화:
|
볼륨(24시간):